Recruiting

Comparing Two Chemotherapy Combinations for HER2-Positive Breast Cancer

Plain-English translation of NCT07057427 on ClinicalTrials.gov ↗ · Source last updated July 2025 · Translation generated July 2026 · How we translate trials

Read our Breast Cancer research guide →

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing whether nab-paclitaxel, a type of chemotherapy drug, works as well as the standard chemotherapy combination (docetaxel plus carboplatin) for treating HER2-positive breast cancer. Both groups also receive two targeted medicines called trastuzumab and pertuzumab. The goal is to find out if the medication offers a better or equally effective option with potentially fewer side effects.

Doctors want to improve treatment options for patients with HER2-positive breast cancer, which is an aggressive type that grows faster. This treatment aims to shrink tumors before surgery, and researchers believe the medication may work just as well as standard chemotherapy while being easier on the body.

Do you qualify?

You likely qualify if…

you are between 18 and 70 years old
you have been diagnosed with HER2-positive invasive breast cancer that is in an early stage (not spread to distant organs)
your cancer tumor is at least a certain size or involves lymph nodes, confirmed by imaging within the past month
your heart, liver, and kidney function are normal or near-normal based on recent blood tests
your heart's pumping ability is strong enough (ejection fraction of 55% or higher)
you have good overall health and can tolerate chemotherapy

You likely don't qualify if…

you have advanced cancer that has spread to other parts of your body (stage IV)
you have cancer in both breasts
you have already received chemotherapy, radiation, or other cancer drugs for this diagnosis
you have significant heart problems, such as a history of heart failure, severe arrhythmias, or poorly controlled high blood pressure
you have a known allergy to any of the study drugs or a compromised immune system

What participation looks like

You will be randomly assigned to receive one of the two chemotherapy combinations given through an IV infusion every three weeks for several cycles. Throughout your treatment, you will have regular visits to the hospital or clinic for infusions, blood tests, and heart monitoring. The treatment is designed to shrink your tumor before you have surgery, and your doctor will track how well the treatment is working through imaging scans.

AI-generated summary from trial data · Jul 12, 2026 · Not medical advice

Trial locations(1 site)

China

Henan cancer hospital, Zhengzhou, Henan